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Background: Various microRNAs (miRNAs) are up- or downregulated in tumors. However, the repression of
cognate miRNA targets responsible for the phenotypic effects of this dysregulation in patients remains largely
unexplored. To define miRNA targets and associated pathways, together with their relationship to outcome in
breast cancer, we integrated patient-paired miRNA-mRNA expression data with a set of validated miRNA targets
and pathway inference.
Results: To generate a biochemically-validated set of miRNA-binding sites, we performed argonaute-2
photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (AGO2-PAR-CLIP) in MCF7 cells. We
then defined putative miRNA-target interactions using a computational model, which ranked and selected additional
TargetScan-predicted interactions based on features of our AGO2-PAR-CLIP binding-site data. We subselected modeled
interactions according to the abundance of their constituent miRNA and mRNA transcripts in tumors, and we took
advantage of the variability of miRNA expression within molecular subtypes to detect miRNA repression. Interestingly,
our data suggest that miRNA families control subtype-specific pathways; for example, miR-17, miR-19a, miR-25, and
miR-200b show high miRNA regulatory activity in the triple-negative, basal-like subtype, whereas miR-22 and miR-24
do so in the HER2 subtype. An independent dataset validated our findings for miR-17 and miR-25, and showed a
correlation between the expression levels of miR-182 targets and overall patient survival. Pathway analysis associated
miR-17, miR-19a, and miR-200b with leukocyte transendothelial migration.
Conclusions: We combined PAR-CLIP data with patient expression data to predict regulatory miRNAs, revealing poten-
tial therapeutic targets and prognostic markers in breast cancer.Background
Breast cancer is a heterogeneous disease involving vari-
ous tumorigenesis mechanisms manifesting at the DNA,
RNA, and protein level. Patients are classified by estro-
gen receptor (ESR/ER), progesterone receptor (PGR/PR),
and ERBB2/HER2 amplified oncogene expression based
on immunohistochemistry, molecular subtypes based on
mRNA expression signatures (luminal, basal-like, HER2,
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[1]. Prognostic mRNA expression signatures have been
defined for specific sets of breast tumors [2,3], but given
the heterogeneity of patient outcomes within the same
subtype, it is clear that pathways regulating tumor aggres-
siveness remain to be further elucidated. miRNAs have
shown promise as therapeutic targets in cancer, suggested
by the recent introduction of the first miRNA mimic in
Phase I cancer clinical trials, and as diagnostic/prognostic
markers, suggested by their cell-type specificity. Onco-
genic and tumor suppressive miRNAs have been impli-
cated in the regulation of critical cellular pathways, such
as differentiation and apoptosis, across several tumor
types [4-6], but identifying miRNA target regulation/re-
pression in tumor samples remains challenging.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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miRNA and mRNA expression in breast tumors as well
as the role of miRNA expression in prognosis, using
samples from variable molecular subtypes, but a clear con-
clusion has yet to be reached (Additional file 1: Table S1)
[7-12]. The Cancer Genome Atlas (TCGA) published
same-sample miRNA and mRNA expression profiles for a
large patient collection (n = 797) determined by sequen-
cing but has not commented on miRNA targeting activity
and prognosis [13]. Finally, a recent study including 1,302
breast tumors, utilizing miRNA and mRNA expression by
microarrays, did not determine direct miRNA target re-
pression [14]. The variability of findings, some of which is
due to technical limitations of quantification methods,
highlights the need for further studies and detailed exam-
ination of approaches used for correlation analysis aimed
at establishing regulatory relationships between miRNAs
and their targets in patient samples.
We recently reported miRNA profiles of a well-
characterized breast cancer collection (n = 179) using small
RNA cDNA library preparation and deep sequencing, with
161 of these also studied using mRNA microarrays [15].
Here, we used the patient miRNA and mRNA expression
profiles, TargetScan predictions [16] and AGO2-PAR-CLIP
[17] to identify miRNA targets (Figure 1). First, we selected
miRNAs and mRNAs from the patient data based on their
expression levels and conducted the analysis within mo-
lecular subtypes. Our study differs from earlier studies in
that it includes miRNA binding sites determined experi-
mentally by AGO2-PAR-CLIP in ductal MCF7 cells. We
defined a list of validated miRNA-target interactions by
using the experimentally supported AGO2-PAR-CLIP in-
teractions and training a regression model to rank and se-
lect miRNA target interactions from TargetScan predictions
that display similar characteristics to AGO2-PAR-CLIP
targets. We then prioritized miRNA regulatory activity
based on association with expression of respective validated
targets, as well as association with KEGG pathways and
known cancer genes. Finally, we predicted outcome among
molecular subtypes based on miRNA and respective target
expression. We validated and compared our results in two
independent datasets: TCGA [13] and NKI295 [3]. We pro-
vide the prioritization of miRNA targets, miRNA pathway
association, and miRNA activity in a web-based format that
can be easily sorted for molecular subtype and dataset, and
searched for a particular miRNA, mRNA target, and path-
way [18].
Results
Correlations between miRNA families and their targets
depend on mRNA and miRNA abundance
We conducted correlation analysis of the same-sample
miRNA-mRNA expression from 161 patient samples
from our earlier study [15], and a selection of 444samples from the TCGA study [13]. Our samples included
normal breast, ductal carcinoma in situ (DCIS), and inva-
sive ductal carcinoma (IDC), comprising a variety of
molecular subtypes. TCGA samples included invasive
breast carcinomas also comprising a variety of molecular
subtypes. In our dataset miRNA abundance was measured
as relative read frequency (RRF) and mRNA abundance
as the average fluorescence intensity from both channels
of Operon arrays (A-value, see Materials and methods).
In the TCGA dataset miRNA and mRNA expression
levels were determined by sequencing; the miRNA abun-
dance reported as RRF and mRNA abundance as reads
per kilobase per million (RPKM). We confirmed that
intronic miRNAs and their host protein-coding genes
were positively correlated and established thresholds for
miRNA abundance, selecting a threshold of 1e-4 RRF (see
Materials and methods; Additional file 2: Figure S1 and S2).
To assess direct miRNA-target repression, we investi-
gated whether correlations between expression of miRNAs
with their computationally predicted-targets were more
negative compared to all remaining miRNA-mRNA corre-
lations, and explored whether mRNA abundance thresh-
olds influenced the strength of the correlations. There are
many miRNA target prediction algorithms, previously
reviewed in depth [19-21]. TargetScan [16] and miRanda
[22] demonstrated similar performance when evaluating
the significance of enrichment of negative correlations be-
tween miRNAs and their targets in datasets from TCGA
[23]. In addition to canonical miRNA targets defined by
both algorithms, miRanda also determines non-canonical
miRNA targets, computing a miRSVR score as the
weighted sum of a number of sequence and context fea-
tures of the predicted miRNA-mRNA duplex [22]. Our
analysis showed that a larger set of conserved TargetScan-
predicted targets performed similarly to a smaller set of
stringent miRSVR scoring miRanda-predicted targets
(Additional file 2: Figure S3) [22]. Thus, we chose to con-
duct our analysis using conserved TargetScan-predicted
targets focusing on miRNA seed families to group miR-
NAs with similar regulatory potential. When we refer to
miRNA correlations with their respective targets we refer
to miRNA seed families as defined by TargetScan (refer-
enced by the miRNA member of the lowest number).
Similarly to Dvinge et al., we did not observe a signifi-
cant difference of the medians of the correlation distri-
bution for all conserved miRNA-TargetScan target pairs
compared to the correlation distribution of all remaining
miRNA-mRNA pairs [14] (Figure 2). Considering that
microarray mRNA expression data are less accurate in
detecting poorly expressed transcripts, we investigated if
the difference of the medians of the two correlation dis-
tributions (as quantified by the Wilcoxon-rank-sum-test)
depended on a threshold of mRNA abundance (Figure 2,
Additional file 2: Figure S1E-F). We set a threshold on








Train and test regression model to predict PAR-CLIP 
miRNA-target pairs
Prioritization (target effect, pathway ass., cancer ass.)
Breast cancer outcome prediction
TCGA, NKI295
Select miRNA and mRNA thresholds + subtype behavior
miRNA – pathway association
Figure 1 Overview of analysis.
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the threshold and computed the Pearson correlation be-
tween expression of miRNA families and their TargetScan
targets. The difference of the medians of the two correl-
ation distributions increased at a higher mRNA abun-
dance threshold. To allow inclusion of a large number of
mRNAs, we selected an mRNA abundance threshold of
A >6.5 including 7,398 mRNAs (out of 16,783), resulting
in a difference of 0.005 between the medians of the two
correlation distributions (P value = 5.01e-6). For the TCGA
dataset, using all 18,152 sequencing-detected mRNAs
resulted in a difference between the medians of the two
correlation distributions of 0.02 (P value = 6.8e-120), sug-
gesting that an abundance threshold was not required
(Additional file 2: Figure S2C-D). With the mRNA abun-
dance thresholds defined above, higher expressed miRNAs
overall demonstrated a more negative correlation with
their respective TargetScan targets, having a larger effect
on their targets and supported the previously selected
threshold of RRF >1e-4 (Additional file 2: Figure S1G-H
and S2E-F).
Correlation analysis within molecular subtypes reveals
varying degrees of miRNA target repression
Molecular subtypes with variability in expression of their
dominant miRNAs, but less variability in their mRNAexpression, are more likely to display negative miRNA-
TargetScan-target correlations. Therefore, we conducted
miRNA-mRNA correlation analyses by molecular sub-
types of breast cancer [24] using the miRNA/mRNA
abundance thresholds defined above. Our dataset [15]
included 78 basal-like, 23 HER2, 25 luminal A, six lu-
minal B, and 21 normal-like samples (10 carcinomas
and 11 normal breast); eight samples could not be
assigned to a particular subtype [25]. The 444 TCGA
samples were subdivided to molecular subtypes using
the PAM-50 classification scheme based on Agilent
microarray data (84 basal, 52 HER2, 205 luminal A, 103
luminal B) [26].
Samples belonging to individual subtypes showed dis-
tinct differences of the medians of the correlation distribu-
tions comparing expression of miRNA-TargetScan-target
pairs and all remaining miRNA-mRNA pairs: basal-like
(-0.0088), luminal A (-0.0096), and normal-like (-0.011)
(Wilcoxon-rank-sum test P value <0.05); the difference
for the HER2 subtype (+0.0076) was not significant,
even though it included a similar number of samples
to the luminal A subtype (Figure 3). The TCGA dataset
demonstrated similar results: the largest differences of
median correlation values were noted for the basal-like
(-0.018), luminal A (-0.026), and luminal B subtype (-0.017);
the HER2 subtype displayed the smallest difference (-0.013)
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Figure 2 MiRNA and mRNA abundance thresholds in patient
datasets. Dependence of Wilcoxon-rank-sum test P value of the
difference of the medians of the distribution of miRNA-TargetScan-
target correlations compared to the distribution of the remainder
miRNA-mRNA correlations on selected threshold for mRNA (A) or
miRNA abundance (B). Results shown for all samples in [15].
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ferent molecular subtypes displayed distinct correla-
tions between expression of specific miRNA families
and their respective top 10 anti-correlated conserved
TargetScan-predicted targets among all samples, either
in our or the TCGA dataset. For example, miR-17 family
expression showed the strongest negative correlation with
its targets within the basal-like subtype (Additional file 2:
Figure S4). The rank of all miR-17 targets based on their
anti-correlation with miR-17 expression between our data-
set and the TCGA dataset showed fair concordance, with
a Spearman correlation coefficient of 0.48 (P value <0.05)
(Additional file 3: Table S2). To better quantify subtype-
specific miRNA regulation, we rank miRNA-target associ-
ations within subtypes later in the manuscript.
AGO2-PAR-CLIP-defined biochemical miRNA targets in
MCF7 breast cancer cell line
To identify which miRNA-target pairs are more likely to
display regulation, we used AGO2-PAR-CLIP [17] to
capture biochemical miRNA targets and define theirspecific location within 3′ UTRs and CDSs, in the
MCF7 luminal subtype and ER-positive/HER2-negative
breast cancer ductal cell line [27]. Even though MCF7
cells display distinct mRNA profiles compared to cell
lines belonging to the basal-like subtype (cell line sub-
types defined in [27]), they share many abundant miR-
NAs with other breast cancer cell lines and tumors
across all molecular subtypes [15]. MCF7 cells exhibit a
drastic upregulation of miR-21, similar to breast tumors
when compared to normal breast tissue [15].
We utilized a monoclonal anti-AGO2 antibody to iso-
late AGO2-associated RNAs [28,29]. Cells are grown in
the presence of 4-thiouridine, which is incorporated into
nascent RNA subsequently resulting in T-to-C conversion
in cDNA reads recovered from crosslinked RNA to
AGO2. The T-to-C conversion is a marker of selecting
RNAs associated with AGO2 rather than background
RNAs [17]. Our dataset demonstrated 80% and 40%
T-to-C conversion for mRNA and miRNA reads, respect-
ively, indicating the isolated RNAs were indeed cross-
linked. The 341,490 mRNA-annotated sequences grouped
into 4,879 clusters distributing across 2,539 transcripts
(Additional file 4: Table S3A). The majority of reads (86.8%)
were exonic, of which 73.6% were located in the 3′ UTR,
24.2% in the CDS and only 2% in the 5′ UTR (Figure 4A).
Crosslink-centered regions (CCRs) comprising 20 nucle-
otides (nt) upstream and downstream of the major T-to-C
conversions within a cluster were generated to calculate
all 16,384 possible 7-mers within the CCRs: the most
significantly enriched 7-mers, relative to random se-
quences of the same dinucleotide composition corre-
sponded to the reverse complement of the seed region
(position 2-8) and other 7-mer combinations of abundant
MCF7 miRNA families (let-7, miR-15a, miR-141, miR-17,
miR-130a, miR-19a) (Table 1), consistent with previous
observations in HEK293 cells [17]. Even though miR-21
was the most sequenced crosslinked miRNA, its comple-
mentary seed sequence was not identified among the top
20 7-mers. The enriched 7-mers were positioned 1-2 nt
downstream of the predominant crosslinking site within
the CCRs (Figure 4B), residing in the unpaired regions
of the AGO protein ternary complex [30] as previously
described [17]. We confirmed that enrichment of com-
plementary 6- through 10-mer sequences to position 1-10
of the most abundant miRNAs was statistically significant
within the isolated mRNAs compared to random sequences
of the same di-nucleotide composition (Additional file 4:
Table S3B-C) and produced a validated list of 7-mer
m8 and 7-mer 1A miRNA target sites [31] (Additional
file 4: Table S3D). This resulted in 3,597 canonical
miRNA-target interactions, with some CCRs containing
target sites for more than one miRNA. We focused on
canonical miRNA binding sites, given that a previous
study in our lab using AGO-PAR-CLIP in HEK293 cells




TCGA (all detected mRNAs)
Farazi (mean A value>6.5)
Difference of the medians of the two correlation distributions
0.005 0.01
Figure 3 Strength of negative miRNA-target correlations across molecular subtypes. The difference of the medians of the distribution of
conserved miRNA-TargetScan-target correlations compared to the distribution of the remainder miRNA-mRNA correlations for each molecular
subtype. Results shown for [15], using an mRNA abundance threshold of mean A value >6.5, and [13], using all detected mRNAs.
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Other recently described methodologies could be used
to focus on non-canonical sites, but have not been dir-
ectly compared to PAR-CLIP [32].
Regression model predicts additional miRNA targets
TargetScan lists theoretically possible target sites within
annotated 3′ UTRs, whereas PAR-CLIP provides evi-
dence for expressed targets within MCF7 cells, and de-
pending on sequencing depth may not have covered
low-level-expressed miRNAs that may be more abun-
dant in patient samples within different molecular sub-
types. Using PAR-CLIP, we identified 3,597 canonical
miRNA-target interactions (assuming seed sequence
complementarity, including targets in the 3′ UTR and
CDS), 2,584 of which were predicted by TargetScan
(1,507 conserved and 1,077 non-conserved). To identify
additional-subtype-specific miRNA targets from the
large number of miRNA-TargetScan-target interactions
(72,770 conserved and approximately 3.5 million non-
conserved) and prioritize them, we followed a supervised
machine learning approach (elastic net regression model;
combination of LASSO and ridge regression). The goal
of this approach was to build a model that can predict,
based on characteristics of the miRNAs and their tar-
gets, whether a miRNA-target interaction is, in fact, a
true interaction as determined by PAR-CLIP. As inputs
to this model we used characteristics of the PAR-CLIP
identified targets (number of 7-mer and 8-mer sites,
conservation and context score derived from TargetS-
can) and their expression levels in patient subtypes
(Additional file 5: Table S4 and Materials and methods
for description). The training and test sets were con-
structed using all miRNA-TargetScan-target pairs that
are: (1) expressed according to our miRNA and mRNA
abundance thresholds in patients for each subtype; and (2)
include an AGO2-crosslinked mRNA target (n = 10,200
for luminal A subtype). We used 5,106 for training the
model and the remainder for testing model performance.
As positive set we employed the crosslinked and PAR-
CLIP-site seed-matched miRNA-TargetScan-target pairs
(n = 561 for luminal A subtype). As negative set we
employed crosslinked, but not PAR-CLIP-site seed-matched, miRNA-TargetScan-target pairs (n = 4,545)
(Additional file 2: Figure S5). Our trained model allowed
us to predict and rank miRNA-TargetScan-target pairs
based on their likelihood of being ‘PAR-CLIP-like’ interac-
tions (further details in Materials and methods).
For the luminal A subtype (which is the closest match
to the MCF7 cell line in which the PAR-CLIP targets
were determined), we obtained an area under the curve
(AUC) of 0.73 for both training and test sets (Additional
file 2: Figure S5). We chose a 0.5 threshold on the pos-
terior probability, resulting in an FDR of approximately
0.5 (Figure 4C). We evaluated 12,925 conserved and
45,293 non-conserved miRNA-TargetScan-target inter-
actions (meeting our miRNA and mRNA thresholds).
We predicted 283 interactions from all TargetScan inter-
actions, 41 of which were supported by PAR-CLIP, thus
identifying 233 conserved and 9 non-conserved add-
itional target interactions (additional 14%) [18]. These
interactions involved 23 miRNA families, mainly let-7
and miR-29a. Model-predicted targets not identified by
PAR-CLIP exhibited a median RPKM expression of 5 in
MCF7 cells, compared to 14 for targets supported by
PAR-CLIP (expression from [33]). This suggested that
the regression model adds not only targets for highly
expressed miRNAs in patient tissues (38 interactions in-
cluding miR-125, miR-142-3p, miR-145, miR-199a, miR-
21 and miR-34a), but also miRNA targets abundant in
patient tissues missed from PAR-CLIP due to their lower
abundance in MCF7 cells.
We observed a greater difference of the medians of
the distribution of correlations for miRNA families and
their model-predicted targets compared to the distribu-
tion of correlations of remaining miRNA-mRNA pairs,
as opposed to miRNA-Targetscan targets and PAR-
CLIP targets, supporting our approach (Figure 4D).
The TCGA dataset showed similar results (Additional
file 2: Figure S6).
We defined miRNA targets by taking the union of the
biochemical PAR-CLIP and regression model-predicted
targets calculated within each molecular subtype to
focus on experimentally tractable targets. Irrespective of
their behavior in patient data (inherent with variability
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TargetScan conserved (n=12925, shift=−0.00963, p=6.47e−05)
PAR-CLIP (n=1766, shift=−0.00239, p=0.381)
Model predicted (n=283, shift=−0.0751, p=1.85e−05)
Model predicted/PAR-CLIP union (n=2008, shift=−0.00954, p=0.058)
Model predicted/PAR-CLIP intersection (n=41, shift=−0.105, p=0.0327)
all other miRNA-mRNA pairs
Figure 4 AGO2-PAR-CLIP summary and regression model characteristics for the luminal A subtype [15]. (A) Genomic location of
PAR-CLIP isolated mRNAs and distribution of AGO2 binding sites in transcript regions. Number of sequences included in clusters (clusters defined
with ≥5 reads). (B) Representation of the 20 most significantly enriched 7-mer sequences within PAR-CLIP CCRs. T/C indicates the predominant
T-to-C conversion defined by CCRs. (C) Regression model positive predictive value as a function of selected posterior probability score threshold
on the left; AUC plot on the right. (D) Correlation density of expression of miRNA families and their conserved TargetScan, PAR-CLIP identified
and model-predicted targets compared to the correlation density of all other miRNA and mRNA pairs.
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Table 1 Top expressed miRNA TargetScan families in
MCF7 cells
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http://genomebiology.com/2014/15/1/R9as feedback regulation) PAR-CLIP targets are supported
by crosslinking evidence in a breast cancer cell line at a
binding site resolution, while model-predicted targets
resemble PAR-CLIP targets and result in a greater differ-
ence of the medians of the two correlation distributions.
We will refer to this set of miRNA-target pairs as
the Model Predicted and PAR-CLIP (MP-PCLIP) pairs
(n = 2,008 in the luminal A subtype: 1,766 from PAR-
CLIP and an additional 242 from model prediction).
To understand the contribution of each individual
input to predict PAR-CLIP targets we conducted univar-
iate correlation analyses (Additional file 5: Table S4).
TargetScan total context score, aggregate conservationscore, and number of conserved 7-mer and 8-mer sites
showed the highest correlation to PAR-CLIP status,
hence providing the most predictive power in the model
[18,31,34]. We also observed that miRNA abundance in
patient samples correlated with PAR-CLIP status, sup-
porting a threshold in miRNA abundance required for
measureable regulation of mRNAs.
miRNA pathway associations across molecular subtypes
After selecting miRNA targets expressed in the different
patient subtypes from the MP-PCLIP pairs, we used
the Global Test (GT) to analyze miRNA-mRNA associa-
tions in the context of KEGG pathways [35]. The GT
can be used to determine whether the global expression
pattern of a group of gene sets is significantly related to
a variable, as supported by either negative or positive
correlations. We assessed whether miRNA expression
significantly associated with expression of genes belong-
ing to KEGG pathways (obtaining a GT P value for the
association; results for each individual subtype and data-
set can be obtained at [18]. The majority of miRNA-
pathway associations that included MP-PCLIP targets,
included a negative correlation between the miRNA
and at least one of its respective targets. For the majority
of miRNAs, miRNA-pathway associations that included
an MP-PCLIP target showed lower P values compared
to miRNA-pathway associations that did not (t-test
P value <0.05), further validating our approach (Additional
file 6: Table S5).
For example, in the basal-like subtype, miRNA associ-
ated pathways included 1-469 expressed genes, of which
1-13 were MP-PCLIP targets, demonstrating negative or
positive correlations to their regulating miRNA. Heatmaps
of the GT association P values for each miRNA family
expression with expression of genes belonging to each
KEGG pathway, revealed different numbers of miRNA
family-KEGG pathway associations in different molecular
subtypes (Figure 5 and Additional file 2: Figure S7).
The associations including an MP-PCLIP target are
highlighted with a star. Moreover, pathways including
miRNA-seed-matched PAR-CLIP targets illustrate ac-
tivity in ductal cells.
As expected, most pathways were targeted by more than
one miRNA. There was a large number of significant
pathway associations for the miR-17, miR-19a, and miR-
25 families in the basal-like subtype, with very few signifi-
cant associations in the HER2 subtype in our dataset. The
most significant miRNA-pathway association in the basal-
like subtype was the association of miR-17 family with
leukocyte transendothelial migration (P value = 3.5e-8), in-
cluding a negative correlation between miR-17 family and
its PAR-CLIP identified target CXCL12 [18] (Additional
file 2: Figure S8). In the TCGA dataset, similarly to our
dataset, miR-17 and miR-25 families showed many pathway
A B
Figure 5 miRNA-KEGG pathway associations. Heatmaps depicting significant P values from GT correlating expression of miRNA families to
genes belonging to KEGG pathways for different subtypes in [15]. Heatmaps for HER2 and luminal A subtype ordered according to the clustering
of the basal-like subtype. Boxes labeled with stars illustrate presence of MP-PCLIP targets. Region selected by red outline represents area with
highest concentration of significant P values seen in panel B. Color key depicts P values of associations. miRNAs in red include pathway gene
associations with MP-PCLIP targets, while pathways in yellow do not.
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HER2 subtype.
Ranking miRNA regulatory activity and tumor phenotype
association across molecular subtypes
To elucidate miRNA-mediated regulation in the context
of tumorigenesis, we performed an overall ranking of
miRNAs by combining a number of evidence sources[36]. There are three components we considered in pri-
oritizing miRNA regulatory activity: (1) association with
its respective targets; (2) association with pathways - in-
dicative of the miRNA’s ability to regulate its targets and
in turn the pathways they regulate; and (3) association
with cancer-related genes. A miRNA ranks high
if achieving a high score (low P value) for each of the
following statistical tests: (1) association of miRNA
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http://genomebiology.com/2014/15/1/R9expression to expression of its respective targets based on
the GT P value; (2) association of miRNA expression with
expression of genes belonging to a KEGG pathway contain-
ing at least one MP-PCLIP target displaying either a nega-
tive or positive correlation with the miRNA (indicating
functional relevance) (smallest GT P value out of all tar-
geted pathways in KEGG); and (3) association of miRNA
expression with expression of the gene set representing the
Cancer Genome Census, modeling cancer relevance (GT
P value) (see Materials and methods for further details).
Each of the three tests is weighted equally in the ranking [36].
The top-scoring significant miRNA families of the
overall ranking (using the significance test from [36]) in
the basal-like subtype were miR-17, miR-19a, and miR-Table 2 Top scoring miRNA TargetScan families in the Farazi
miRNA expression





























Ranking of miRNA regulatory activity. Significant results shown for [15] and [13] (P v
expression and variability.25 belonging to the oncogenic mir-17~92 cluster [37],
and miR-200b, involved in the epithelial-mesenchymal
transition [38] (Table 2) [18]. MiR-17 and miR-25 were
also identified in the TCGA dataset. Expression of miR-
17, miR-19a, and miR-200b targets was associated with
distant metastasis-free survival in the basal-like subtype
in a large cohort of breast cancer samples (see analysis
in following section). Ranking of miRNA regulatory ac-
tivity in the basal-like subtype showed fair concordance
between our and the TCGA datasets, demonstrating a
Spearman correlation coefficient of 0.47 (P value <0.05).
MiR-24 was significant within the HER2 subtype, with
miR-22 ranking second in our dataset (P value = 0.058).
MiR-22 ranked second in the HER2 subtype in theand TCGA datasets
miRNA activity
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tical significance in the luminal B subtype (P value = 0).
At the same time, to elucidate miRNA tumor pheno-
type association in each subtype, we performed a second
overall ranking of miRNAs by combining a set of evi-
dence sources associated with patient histopathological
and clinical characteristics, using the rank test described
above [36]. These are GT P values assessing whether ex-
pression of miRNA families and their respective targets
significantly related to development of distant metastasis
and overall survival, number of positive lymph nodes,
tumor size, lymphovascular invasion, and histological
grade. The highest scoring miRNA family in our dataset
was miR-130a in the basal-like subtype (Additional file
7: Table S6), regulating angiogenesis [39]. In the NKI295
dataset, which was used for validation of these results,
miR-130a family ranked third, but did not reach statis-
tical significance (Additional file 7: Table S6). Expression
of miR-130a targets was also associated with distant
metastasis-free survival and relapse-free survival in the
basal-like subtype in a large cohort of breast cancer
samples (see analysis in following section). Expression of
miR-203 targets (implicated in cancer stem cell charac-
teristics [40]) significantly correlated with lymphovascu-
lar invasion in the basal-like subtype in our dataset, a
finding also supported in the luminal A subtype in the
NKI295 dataset. It is interesting to note that the top
ranked miRNAs according to regulatory activity do not
necessarily overlap with the top ranked miRNAs accord-
ing to association with tumor phenotype, but may be
more interesting candidates for targeted therapy as they
have a detectable regulatory role.
Expression of miR-182 targets predicts metastasis
To determine whether expression levels of miRNAs and
their respective targets predicted metastasis and overall
survival, we used the GT with Cox-regression in our and
the NKI295 study [3] (Additional file 7: Table S6). The
NKI295 study includes mRNA microarray expression for
295 samples (55 luminal B, 123 luminal A, 29 normal-
like, 53 basal-like, and 35 HER2). We selected 283
samples from patients with metastasis as first event to
compare to our dataset. TCGA only reports overall sur-
vival with a short follow-up (average = 736 days), so we
did not use it in this analysis. Expression of miR-182 tar-
gets, recently reported to be involved in breast cancer
metastasis [41], was significantly associated with overall
survival when considering all NKI295 patients. This
prognostic signature comprised 12 genes with expression
in the NKI295 series (XBP1, IGF1R, THBS1, PLAGL2,
YWHAG, ZFP36, PSMC2, CCNG1, HSPA8, PFN1, ADCY6,
NUP50). MiR-182 regulatory activity ranked fourth in
the HER2 subtype in the TCGA dataset. None of the re-
sults within individual subtypes in our and the NKI295dataset reached statistical significance after multiple
testing correction and multivariate analysis accounting
for histologic grade, tumor size, and lymph node status.
However, we did notice weak concordance in the rank-
ing of metastasis prognostic signatures between our
and the NKI295 datasets in the basal-like and HER2
subtypes (correlation 0.35 and 0.43, P value <0.05). Fi-
nally, we further assessed the miRNA target prognostic
signatures in two additional datasets (n = 623 (distant
metastasis-free survival) and n = 1,616 (relapse-free
survival)), using normalized mRNA expression from a
large cohort of breast cancer samples [42,43]. The clinical
and histopathological characteristics were unavailable, so
we could not conduct multivariate analysis for these data-
sets. miR-183, which is co-expressed with miR-182, was
the top prognostic signature in these datasets, with miR-
182 still maintaining significance, providing some support
for our results (Additional file 7: Table S6).
Discussion
Functional studies in breast cancer cell lines and mouse
models have suggested multiple roles played by miRNAs
in the development of breast carcinomas and their meta-
static potential involving targets regulating many cellular
pathways. However, which miRNA-target pair(s) is (are)
important in human disease progression is not always
predicted by cell culture or animal model studies alone.
Here we examined the extent of correlation in mRNA
and miRNA expression in large sample collections by
prioritizing the effects of miRNAs on many targets.
High miRNA abundance is critical for experimental
analysis of transcriptome-wide seed-dependent target
mRNA repression [44-47]. In our study we showed the
importance of miRNA and mRNA abundance thresholds
to focus on more reliably quantified and molecularly
validated miRNA targets to conduct computational ana-
lysis of miRNA-mRNA correlations in tumor samples.
The recent study by Dvinge et al. [14] did not impose
sequence-based derived thresholds for miRNA expres-
sion and did not document miRNA repression in breast
cancer, as suggested by lack of enrichment of negative
correlations for miRNA-target pairs. Our approach doc-
umented miRNA and mRNA expression changes con-
sistent with miRNA target regulation and focused on
miRNA-target pairs based on their crosslinking to
AGO2 through PAR-CLIP. This limited the large num-
ber of possible miRNA-TargetScan-target pairs to ex-
perimentally tractable pairs.
Even though miR-21 is highly expressed both in MCF7
cells and patient breast tumor samples, we were only
able to identify a small number of its targets crosslinked
by AGO2-PAR-CLIP. A recent article sheds some light
into the targeting behavior of miR-21 [48]. They showed
that miR-21 exhibited poor mRNA silencing activity in
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expressed miRNAs in this tissue, and suggested that re-
duced thermodynamic stability of seed pairing and target
binding may contribute to this effect. At the same time,
they were able to document target miR-21 regulation in
HeLa cells, suggesting that the effect may be modulated
by competition from AU-rich-RNA-binding proteins dif-
ferentially expressed in distinct cell types.
We showed that conducting the analysis in each tumor
subtype pointed to miRNAs and associated pathways
that may represent therapeutic targets for specific
groups of patients. Members of the mir-17~92 cluster
had high miRNA regulatory activity (Table 2) in the
basal-like subtype both in our and the TCGA dataset.
MiR-17 and miR-19a families were associated with the
leukocyte transendothelial migration pathway, with simi-
larities to metastasis, and were negatively correlated with
their PAR-CLIP target CXCL12. CXCL12, involved in
metastasis [49], was also a PAR-CLIP target of other
miRNA families (miR-7, miR-23a, miR-182, and miR-
183) (Additional file 2: Figure S8).
Our prioritization of miRNA regulatory activity selects
for miRNAs that show regulation through association
with their respective targets and regulated pathways, as
well as genes implicated in cancer, in distinct molecular
subtypes. We consistently observed regulation by miR-
NAs in the basal-like subtype across two independent
datasets. Detecting miRNA activity and cancer associ-
ation does not necessarily predict whether inhibiting
or over-expressing the miRNA will have therapeutic
benefit - it simply points to the relevance of the priori-
tized miRNA as evidenced by repression of its targets in
patient tissues. Two recent manuscripts also point to the
importance of two of our top prioritized miRNA fam-
ilies: miR-200 and miR-22 [50,51] (Table 2). Song et al.
found that miR-22 regulated breast cancer stemness and
metastasis via TET-family-dependent chromatin remod-
eling. In vitro and in vivo experiments showed that miR-
22 promoted epithelial mesenchymal transition and
tumor invasion and metastasis. Our results point to
high miR-22 activity in the luminal B subtype in the
TCGA dataset, as well as the HER2 subtype in both
datasets (ranked second with P value >0.05 in TCGA
and P value <0.05 in our dataset). Another study by
Pecot et al. showed that the miR-200 family blocked
cancer angiogenesis specifically in the basal-like subtype.
Our results point to high miR-200b family activity in the
basal-like subtype in our dataset.
Conclusions
Abundant miRNAs repress their respective targets in
breast tumor-related processes, as documented by regula-
tion of their targets in patient tissues. This regulation is
subtle and may not be readily revealed in global analysiswith a moderately large number of patient samples, but
only by using approaches involving data curation and bio-
chemical evidence, relying on miRNA sequencing-derived
abundance. Moreover, this regulation may only be evi-
dent when conducting the analysis within individual mo-
lecular subtypes: for example, the extent of regulation as
supported by pathway association in the HER2 subtype is
less pronounced compared to the other subtypes.
We can only detect regulation for few highly abundant
miRNAs, and can only validate three of these miRNAs
across two independent datasets. Challenges and caveats
to interpretation of our results include: (1) patient het-
erogeneity between the different patient datasets exam-
ined; (2) noise in the patient mRNA profiles due to the
different platforms used for their detection (that is, se-
quencing vs. microarray); (3) assumptions made for the
detection of miRNA targets, mainly focusing on targets
that exhibit a negative correlation between their re-
spective regulating miRNAs to derive thresholds for
miRNA and mRNA abundance and negative or positive
correlations for miRNA pathway association. Lack of
detection of miRNA activity using our methodology
does not necessarily rule out miRNA-mediated regula-
tion; the analysis, instead, focuses on providing support
from patient data for a few miRNAs that could be con-
sidered promising candidates for therapeutic manipula-
tion. Finally, the challenges in validating prognostic
signatures across datasets are not unique to our study,
but represent frequent complexities arising from breast
cancer heterogeneity and the different sets of genes de-
tected by microarray and/or sequencing methodologies
not allowing a direct comparison of gene expression
signature performance.
In conclusion, we provide a list of miRNA targets, as-
sociated pathways, tumor phenotypes, and miRNA regu-
latory activity derived from patient samples as well as
supported by biochemical evidence, to allow generation
of clinically relevant hypotheses. Our analysis allows def-
inition of a few specific miRNAs as potential therapeutic
targets and prognostic markers in breast cancer and can
be applied to other patient datasets.
Materials and Methods
Datasets and analysis
Our miRNA dataset was reported in [15]. mRNA abun-
dance values (A) correspond to the fluorescence inten-
sity averaged from both dye swap NKI Operon array
experiments: defined as log2(sqrt(R*G)), where R and
G are the red and green fluorescent channels. mRNA
expression was normalized to a set of 100 tumors (log2
(fold-change)). Probes correlating >0.8 were condensed
to genes by averaging probe log2(fold-change). The TCGA
dataset is described in [13] and was downloaded from
([52]; 2013-02). miRNA counts correspond to the most
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each sample and normalized to RRF. Detected miRNAs
were defined as having more than 10 reads in at least 5%
of the samples. Detected mRNAs were defined as having
more than 20 reads in at least 5% of the samples. mRNA
RPKM values of 0 were set to the lowest non-zero RPKM
value measured in a given sample and subsequently log2-
transformed. The NKI295 dataset is described in [3] and
downloaded from [53], with an updated median follow-up
of 12 years.
Intronic miRNAs were obtained from Table S2 in [54].
We excluded miRNAs with multiple copies, as they can-
not be assigned to a single host gene. We used TargetScan
version 6.2 [55] (context score and evolutionary conserva-
tion scores aggregated per gene and miRNA; Summary
Counts file) and miRanda-miRSVR August 2010 release
[56] (miRSVR scores aggregated per gene and miRNA).
KEGG pathways were obtained from BioConductor [57],
the CGC from [58] (Table_1_full_2012-01-18.xls). GT
5.12.0 and glmnet 1.9-3 packages were obtained from Bio-
Conductor version 2.11 (R version 2.15.3; 2013-03-01).
Rank test for miRNA regulatory activity and phenotype
association as described in [36]. Figure 1 and Additional
file 2: Figure S9 describes the analysis outline and provides
examples of the tables generated.
miRNA and mRNA abundance thresholds for patient data
We evaluated thresholds for miRNA and mRNA expres-
sion to focus on higher confidence correlations. We estab-
lished that overall expression of intronic miRNAs and their
protein-coding host genes displayed a positive Pearson cor-
relation, as described in [23,59] (Additional file 2: Figure
S1A-B; Additional file 8: Table S7). We next investigated
whether miRNA abundance influenced the positive corre-
lations observed between expression of intronic miRNAs
and their host genes. In our dataset, the correlation results
for poorly expressed intronic miRNAs near the detec-
tion limit were more variable as compared to higher
expressed miRNAs, which displayed stronger positive
correlations with their host genes (P = 0.001) (Add-
itional file 2: Figure S1C). mRNA abundance did not in-
fluence the correlation between intronic miRNAs and
host genes, likely due to the non-linear variation in our
array-based measurements (Additional file 2: Figure
S1D). Hybridization-based mRNA arrays do not display
the same linear variations for detection of lower expressed
mRNAs, and may also reach saturation during detection
of highly expressed mRNAs. We therefore set the miRNA
expression threshold to an RRF of 1e-4 (corresponding to
an average correlation of 0.28). Given that TCGA was se-
quenced deeper than our dataset (750,000 compared to
5,000 minimum reads per sample), almost all correlations
between expression of intronic miRNAs and their host
genes were positive (Additional file 2: Figure S2A).TargetScan thresholds
Applying more stringent TargetScan thresholds for ag-
gregate conservation/PCT or total context score resulted
in an even greater difference between the medians of the
two correlation distributions at our selected miRNA and
mRNA abundance thresholds (Additional file 2: Figure
S10), further supporting the use of TargetScan.
Global tests
We conducted the following GTs [35] for miRNA regu-
latory activity. First, we conducted a GT evaluating the
association of miRNA expression with expression of its
MP-PCLIP targets (miR ~ target1 + … + targetN). Sec-
ond, we conducted a GT evaluating the association of
miRNA expression with expression of gene sets corre-
sponding to KEGG pathways (miR ~ kegg1.gene1 + … +
kegg1.geneN,…, miR ~ keggK.gene1 + … + keggK.
geneN) (examples can be found in Additional file 2:
Figure S8). Third, we conducted a GT evaluating the as-
sociation of miRNA expression with expression of the
genes comprising the Cancer Gene Census (miR ~ cgc.
gene1 + … + cgc.geneN). For tumor phenotype associ-
ation, we conducted GTs evaluating the association of
expression of a miRNA along with expression of its re-
spective targets (miRNA target expression signature) to
a particular tumor clinical or histopathological charac-
teristic. We used logistic regression for association with
lymph node status and lymphovascular invasion (yes or
no), multinomial regression for tumor size (<2, 2-5, >5
cm) and histologic grade (good, moderate, poor), and
Cox-regression for association with time to metastasis
and overall survival (patient characteristics described in
[15]). Multiple testing correction was conducted using
the Benjamini-Hochberg method.
Regression model
We used a combination of LASSO and ridge multivariate
regression (glmnet package) to predict whether a given
miRNA-TargetScan-target is a PAR-CLIP identified pair
(true or false). As input to the model we employed the fol-
lowing variables: (A) TargetScan: aggregate conservation/
PCT score, total context score, total number of conserved/
non-conserved sites, total number of 7-mer m8, 7-mer
1A, and 8-mer conserved/non-conserved sites; (B) Patient
data: miRNA/mRNA abundance/variance, miRNA-mRNA
interaction terms (miRNA abundance multiplied by
mRNA abundance considering sign of mRNA log2(fold-
change), or irrespective of sign). We viewed the predictive
model as hypothesis generating and not as a final set of
high confidence pairs to have a larger set of miRNA-target
pairs to include in further enrichment and association
studies. Thus, we used a posterior probability prediction
cutoff of 0.5 because it resulted in the best model perform-
ance, as judged by the positive predictive value (PPV) or
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file 2: Figure S5). Increasing the posterior probability pre-
diction cutoff to 0.7 for the TCGA dataset allowed us to
reach an FDR of approximately 25%, but resulted in pre-
diction of only 23 miRNA-target pairs (Additional file 2:
Figure S6). Increasing the mRNA abundance threshold
did not result in improvement in model performance
(Additional file 2: Figure S11). Additional file 2: Figure S12
depicts the distribution of low- and high-expressed genes
in the patient luminal A samples as a function of the
MCF7 cell RPKM expression levels.
Biochemical identification of miRNA targets using
AGO2-PAR-CLIP
MCF7 cells were obtained from ATCC and grown at 37ºC
in an atmosphere containing 5% CO2 in Dulbecco’s modi-
fied Eagle’s medium (1X D-MEM/high-glucose/L-glutam-
ine/sodium pyruvate) supplemented with 10% heat
inactivated fetal bovine serum, 100 unit/mL penicillin, 100
mg/mL streptomycin (Invitrogen, Sigma, and Gibco).
Cells were grown in the presence of 100 μM 4-thiouridine
(4SU) for 24 h and AGO2 complexes were immunopreci-
pitated using a monoclonal antibody against AGO2 (Milli-
pore clone 9E8.2; used in [28,29]), according to [17]. We
used lysis buffer in lieu of high-salt wash buffer to not dis-
rupt the monoclonal antibody-bead interaction. Cross-
linked RNA of 20-40 nt in length was recovered from the
100 kDa AGO2 immunoprecipitated protein complexes
separated on SDS gel, confirmed by Western blot probing
with a polyclonal antibody recognizing AGO2 (Millipore
07-590). The isolated RNA was converted into cDNA li-
braries, and sequenced by Illumina at the Rockefeller Uni-
versity Genomics Center. We analyzed the data similarly
to [17]. The sequence reads were aligned to the human
genome and transcript sequences from public databases,
allowing for up to one mismatch. Overlapping reads >20
nt were clustered, and clusters containing <5 sequence
reads or those with a content of <20% crosslinked se-
quences were not considered. A T-to-C conversation rate
of 80% and 40% was noted for mRNA and miRNA reads,
respectively. The lower T-to-C conversion rate for miR-
NAs was noted in our previous publication [17] and is
likely due to the association of AGO2 with background
abundant non-crosslinked miRNAs (such as, miR-21).
miRNA targets were defined for the 69 top-expressed
miRNAs in MCF7 cells (95% of miRNA sequence reads)
by searching the sequences for complementary miRNA
seed sequence sites (position 2-8, 1-7 perfect match, or
allowing A at position 1), that are enriched within the iso-
lated mRNAs compared to random sequences of the same
di-nucleotide composition. The raw sequencing file is de-
posited with the Sequence Read Archive (SRX388831;
[60]). Finally, we compared the number of conserved Tar-
getScan and high miRSVR scoring Miranda miRNA-targetinteractions validated by PAR-CLIP. Accounting for ex-
pression of potential targets in MCF7 cells (RPKM >14),
PAR-CLIP validated 8.3% of conserved TargetScan-
predicted targets (3,104) and 9.9% of high miRSVR (<-1.2)
scoring Miranda-predicted targets (1,970).
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between the Farazi 2011 and TCGA 2012 datasets for each individual
miRNA within distinct molecular subtypes.
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